Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B

被引：40

作者：

Cuenca-Estrella, M ^{[1
]}

Mellado, E ^{[1
]}

Díaz-Guerra, TM ^{[1
]}

Monzón, A ^{[1
]}

Rodríguez-Tudela, JL ^{[1
]}

机构：

[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Micol, Madrid, Spain

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2000年 / 46卷 / 03期

关键词：

D O I：

10.1093/jac/46.3.475

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The in vitro activity of LY303366 was compared with those of itraconazole and amphotericin B against 156 fluconazole-resistant (MIC greater than or equal to 16 mg/L) clinical isolates of Candida spp. An adaptation of the NCCLS reference method was employed for determination of MICs. LY303366 was more potent than either itraconazole or amphotericin B against Candida albicans, Candida glabrata, Candida krusei and Candida tropicalis, even against isolates with itraconazole MICs greater than or equal to 1 mg/L. LY303366 was less potent in vitro against Candida parapsilosis and Candida guilliermondii isolates. LY303366 has promising antifungal activity and warrants further investigation.

引用

页码：475 / 477

页数：3

共 9 条

[1] In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients [J].

Chávez, M ;

Bernal, S ;

Valverde, A ;

Gutierrez, MJ ;

Quindós, G ;

Mazuelos, EM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) :697-700

[2] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956

[3]

NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS-NCCLS, 1997, M27A NCCLS

[4] Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits [J].

Petraitiene, R ;

Petraitis, V ;

Groll, AH ;

Candelario, M ;

Sein, T ;

Bell, R ;

Lyman, CA ;

McMillian, CL ;

Bacher, J ;

Walsh, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2148-2155

[5] In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents [J].

Pfaller, MA ;

Messer, SA ;

Coffman, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) :763-766

[6] In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi [J].

Pfaller, MA ;

Marco, F ;

Messer, SA ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 30 (04) :251-255

[7] IMPROVED MEDIUM FOR FLUCONAZOLE SUSCEPTIBILITY TESTING OF CANDIDA-ALBICANS [J].

RODRIGUEZTUDELA, JL ;

MARTINEZSUAREZ, JV .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) :45-48

[8] CORRELATION OF IN-VITRO SUSCEPTIBILITY TEST-RESULTS WITH CLINICAL-RESPONSE - A STUDY OF AZOLE THERAPY IN AIDS PATIENTS [J].

RODRIGUEZTUDELA, JL ;

MARTINEZSUAREZ, JV ;

DRONDA, F ;

LAGUNA, F ;

CHAVES, F ;

VALENCIA, E .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (06) :793-804

[9] In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species [J].

Zhanel, GG ;

Karlowsky, JA ;

Harding, GAJ ;

Balko, TV ;

Zelenitsky, SA ;

Friesen, M ;

Kabani, A ;

Turik, M ;

Hoban, DJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) :863-865

← 1 →